Trial Outcomes & Findings for A Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity in a Chinese Population (NCT NCT04950465)
NCT ID: NCT04950465
Last Updated: 2023-10-23
Results Overview
Schiff sensitivity score was assessed by participant's response to an evaporative (air) stimulus after the stimulation of 2 selected test teeth, response of participants were scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. Higher score indicates worst outcome (more sensitivity). Change from baseline was defined as post dose visit value minus baseline visit value. Baseline was defined as Day 1 (visit 2) value.
COMPLETED
NA
271 participants
Baseline and Week 8
2023-10-23
Participant Flow
Participants were recruited from one center in China.
A total of 561 participates were screened, out of which 271 participants were enrolled and 197 participates were randomized to a treatment (66 participants in the test product group, 67 participants in the negative control dentifrice group and 64 participants in the positive control dentifrice group) and 196 participants subsequently completed the study; 1 participant did not complete the study from the test product group due to being lost to follow-up.
Participant milestones
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 milliliters (mL) of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Positive Control (Sensodyne Repair and Protect)
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|---|
|
Overall Study
STARTED
|
66
|
67
|
64
|
|
Overall Study
COMPLETED
|
65
|
67
|
64
|
|
Overall Study
NOT COMPLETED
|
1
|
0
|
0
|
Reasons for withdrawal
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 milliliters (mL) of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Positive Control (Sensodyne Repair and Protect)
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
0
|
0
|
Baseline Characteristics
A Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity in a Chinese Population
Baseline characteristics by cohort
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=65 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Positive Control (Sensodyne Repair and Protect)
n=64 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Total
n=196 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
43.9 years
STANDARD_DEVIATION 8.04 • n=5 Participants
|
42.7 years
STANDARD_DEVIATION 8.55 • n=7 Participants
|
42.4 years
STANDARD_DEVIATION 9.68 • n=5 Participants
|
43.0 years
STANDARD_DEVIATION 8.76 • n=4 Participants
|
|
Sex: Female, Male
Female
|
57 Participants
n=5 Participants
|
64 Participants
n=7 Participants
|
56 Participants
n=5 Participants
|
177 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
19 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
65 Participants
n=5 Participants
|
67 Participants
n=7 Participants
|
64 Participants
n=5 Participants
|
196 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: Baseline and Week 8Population: mITT population
Schiff sensitivity score was assessed by participant's response to an evaporative (air) stimulus after the stimulation of 2 selected test teeth, response of participants were scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. Higher score indicates worst outcome (more sensitivity). Change from baseline was defined as post dose visit value minus baseline visit value. Baseline was defined as Day 1 (visit 2) value.
Outcome measures
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=65 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|
|
Change From Baseline in Schiff Sensitivity Score at Week 8 (Test Dentifrice Versus [vs.] Negative Control)
|
-0.98 Score on a scale
Standard Error 0.099
|
-1.14 Score on a scale
Standard Error 0.098
|
SECONDARY outcome
Timeframe: Baseline, Week 4 and 8Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
Constant pressure was administered using Yeaple Probe. At baseline the upper test limit was 20 gram (g) and at Week 4 and 8, the upper test limit was 80g. The tactile threshold was the maximum pressure applied without the participant reporting pain or discomfort. The tactile threshold for 2 selected test teeth were determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutives 'yes' responses were recorded as the tactile threshold. The greater the tactile threshold, the less sensitive the tooth. Change from baseline was defined as post dose visit value minus baseline visit value. Baseline was defined as Day 1 (visit 2) value.
Outcome measures
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=65 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|
|
Change From Baseline in Tactile Threshold at Week 4 and 8 (Test Dentifrice vs. Negative Control)
Week 4
|
9.22 grams
Standard Error 1.577
|
7.42 grams
Standard Error 1.538
|
|
Change From Baseline in Tactile Threshold at Week 4 and 8 (Test Dentifrice vs. Negative Control)
Week 8
|
16.63 grams
Standard Error 2.393
|
11.82 grams
Standard Error 2.353
|
SECONDARY outcome
Timeframe: Baseline and Week 4Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
Schiff sensitivity score was assessed by participant's response to an evaporative (air) stimulus after the stimulation of 2 selected test teeth, response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. Higher score indicates worst outcome (more sensitivity). Change from baseline was defined as post dose visit value minus baseline visit value. Baseline was defined as Day 1 (visit 2) value.
Outcome measures
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=64 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|
|
Change From Baseline in Schiff Sensitivity Score at Week 4 (Test Dentifrice vs. Negative Control)
|
-0.79 Score on a scale
Standard Error 0.082
|
-0.75 Score on a scale
Standard Error 0.080
|
SECONDARY outcome
Timeframe: Baseline, Week 4 and Week 8Population: mITT population
Schiff sensitivity score was assessed by participant's response to an evaporative (air) stimulus after the stimulation of 2 selected test teeth, response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. Higher score indicates worst outcome (more sensitivity). Change from baseline was defined as post dose visit value minus baseline visit value. Baseline was defined as Day 1 (visit 2) value.
Outcome measures
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=64 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|
|
Change From Baseline in Schiff Sensitivity Score at Week 4 and 8 (Positive Control vs. Negative Control)
Week 4
|
-0.76 score on a scale
Standard Error 0.082
|
-0.75 score on a scale
Standard Error 0.080
|
|
Change From Baseline in Schiff Sensitivity Score at Week 4 and 8 (Positive Control vs. Negative Control)
Week 8
|
-0.99 score on a scale
Standard Error 0.100
|
-1.14 score on a scale
Standard Error 0.098
|
SECONDARY outcome
Timeframe: Baseline, Week 4 and Week 8Population: mITT population
Constant pressure was administered using Yeaple Probe. At baseline the upper test limit was 20g and at Week 4 and 8, the upper test limit was 80g. The tactile threshold was the maximum pressure applied without the participant reporting pain or discomfort. The tactile threshold for 2 selected test teeth determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutives 'yes' responses would be recorded as the tactile threshold. The greater the tactile threshold, the less sensitive the tooth. Change from baseline was defined as post dose visit value minus baseline visit value. Baseline was defined as Day 1 (visit 2) value.
Outcome measures
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=64 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 Participants
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|
|
Change From Baseline in Tactile Threshold at Week 4 and 8 (Positive Control vs. Negative Control)
Week 8
|
11.05 grams
Standard Error 2.412
|
11.82 grams
Standard Error 2.353
|
|
Change From Baseline in Tactile Threshold at Week 4 and 8 (Positive Control vs. Negative Control)
Week 4
|
4.59 grams
Standard Error 1.577
|
7.42 grams
Standard Error 1.538
|
Adverse Events
Test Dentifrice (Sensodyne Sensitivity & Gum)
Negative Control (Crest Cavity Protection Fresh Lime)
Positive Control (Sensodyne Repair and Protect)
Serious adverse events
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=66 participants at risk
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 participants at risk
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Positive Control (Sensodyne Repair and Protect)
n=64 participants at risk
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|---|
|
Gastrointestinal disorders
Obstructive pancreatitis
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Hepatobiliary disorders
Cholecystitis
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
Other adverse events
| Measure |
Test Dentifrice (Sensodyne Sensitivity & Gum)
n=66 participants at risk
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided, followed by brushing of the qualifying sensitive teeth. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Negative Control (Crest Cavity Protection Fresh Lime)
n=67 participants at risk
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
Positive Control (Sensodyne Repair and Protect)
n=64 participants at risk
Participants were instructed to brush their teeth for 1 timed minute with full ribbon of toothpaste on the head of the toothbrush provided. Following brushing they were instructed to rinse once with 10 mL of water from the rinsing cup provided.
|
|---|---|---|---|
|
Gastrointestinal disorders
Dental abfraction
|
6.1%
4/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
4.7%
3/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Mouth ulceration
|
4.5%
3/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.6%
1/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
3.0%
2/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.5%
1/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.6%
1/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Angular cheilitis
|
3.0%
2/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.5%
1/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Lip ulceration
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.5%
1/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.6%
1/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Tooth disorder
|
4.5%
3/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Oral blood blister
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.6%
1/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Gingival erythema
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Gingival swelling
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Injury, poisoning and procedural complications
Lip injury
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Injury, poisoning and procedural complications
Mouth injury
|
0.00%
0/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.6%
1/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Infections and infestations
Pulpitis dental
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Gastrointestinal disorders
Tongue ulceration
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Injury, poisoning and procedural complications
Wound
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Infections and infestations
Influenza
|
0.00%
0/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.6%
1/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
3.1%
2/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Infections and infestations
Pharyngitis
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
1.6%
1/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
|
Eye disorders
Keratitis
|
1.5%
1/66 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/67 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
0.00%
0/64 • From start of screening until end of study (up to Day 57+/-3)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study product including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse outcome is serious.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER